Cargando…

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis

OBJECTIVE: It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraz-Amaro, Iván, Delgado-Frías, Esmeralda, Hernández-Hernández, Vanesa, Sánchez-Pérez, Hiurma, de Armas-Rillo, Laura, Armas-González, Estefanía, Machado, José David, Diaz-González, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901093/
https://www.ncbi.nlm.nih.gov/pubmed/33622410
http://dx.doi.org/10.1186/s13075-021-02443-9
_version_ 1783654334187175936
author Ferraz-Amaro, Iván
Delgado-Frías, Esmeralda
Hernández-Hernández, Vanesa
Sánchez-Pérez, Hiurma
de Armas-Rillo, Laura
Armas-González, Estefanía
Machado, José David
Diaz-González, Federico
author_facet Ferraz-Amaro, Iván
Delgado-Frías, Esmeralda
Hernández-Hernández, Vanesa
Sánchez-Pérez, Hiurma
de Armas-Rillo, Laura
Armas-González, Estefanía
Machado, José David
Diaz-González, Federico
author_sort Ferraz-Amaro, Iván
collection PubMed
description OBJECTIVE: It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients with respect to controls and whether these changes were associated with disease-related data. METHODS: Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. RESULTS: The multivariable analysis adjusted for demographic characteristics, cardiovascular risk factors, and lipid-related molecules showed that total cholesterol (beta coefficient: − 22 [95%CI – 37 to – 7], p = 0.004), triglycerides (beta coefficient: 24 [95%CI 2–47], p = 0.033), lipoprotein A (beta coefficient: 22 [95%CI 2–43], p = 0.033), and CEC (beta coefficient: – 6 [95%CI − 10 to – 2]%,p = 0.002) were significantly different between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: – 0.21 [95%CI – 0.37 to – 0.05]%, p = 0.011) after multivariable adjustment. CONCLUSION: SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02443-9.
format Online
Article
Text
id pubmed-7901093
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79010932021-02-23 HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis Ferraz-Amaro, Iván Delgado-Frías, Esmeralda Hernández-Hernández, Vanesa Sánchez-Pérez, Hiurma de Armas-Rillo, Laura Armas-González, Estefanía Machado, José David Diaz-González, Federico Arthritis Res Ther Research Article OBJECTIVE: It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients with respect to controls and whether these changes were associated with disease-related data. METHODS: Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. RESULTS: The multivariable analysis adjusted for demographic characteristics, cardiovascular risk factors, and lipid-related molecules showed that total cholesterol (beta coefficient: − 22 [95%CI – 37 to – 7], p = 0.004), triglycerides (beta coefficient: 24 [95%CI 2–47], p = 0.033), lipoprotein A (beta coefficient: 22 [95%CI 2–43], p = 0.033), and CEC (beta coefficient: – 6 [95%CI − 10 to – 2]%,p = 0.002) were significantly different between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: – 0.21 [95%CI – 0.37 to – 0.05]%, p = 0.011) after multivariable adjustment. CONCLUSION: SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02443-9. BioMed Central 2021-02-23 2021 /pmc/articles/PMC7901093/ /pubmed/33622410 http://dx.doi.org/10.1186/s13075-021-02443-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ferraz-Amaro, Iván
Delgado-Frías, Esmeralda
Hernández-Hernández, Vanesa
Sánchez-Pérez, Hiurma
de Armas-Rillo, Laura
Armas-González, Estefanía
Machado, José David
Diaz-González, Federico
HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
title HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
title_full HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
title_fullStr HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
title_full_unstemmed HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
title_short HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
title_sort hdl cholesterol efflux capacity and lipid profile in patients with systemic sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901093/
https://www.ncbi.nlm.nih.gov/pubmed/33622410
http://dx.doi.org/10.1186/s13075-021-02443-9
work_keys_str_mv AT ferrazamaroivan hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT delgadofriasesmeralda hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT hernandezhernandezvanesa hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT sanchezperezhiurma hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT dearmasrillolaura hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT armasgonzalezestefania hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT machadojosedavid hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis
AT diazgonzalezfederico hdlcholesteroleffluxcapacityandlipidprofileinpatientswithsystemicsclerosis